JenaValve Technology, Inc.

JenaValve Technology, Inc. is a global medical device company based in Irvine, California, with additional offices in Leeds, U.K., and Munich, Germany. The company specializes in developing and commercializing transcatheter heart valve technologies aimed at treating severe aortic regurgitation (AR). Their flagship product, the Trilogy Heart Valve System, is designed for minimally invasive treatment of this condition, particularly in patients at high surgical risk. The Trilogy System is the first device approved in the European Union for this indication and is also CE-marked for severe aortic stenosis. JenaValve focuses on the development, manufacturing, and sale of the Trilogy System to healthcare providers, including hospitals and clinics. They provide training and support to physicians to ensure effective use of their technology. The company has secured significant funding to support clinical trials, regulatory approvals, and expansion of manufacturing capabilities, positioning itself for a commercial launch in the U.S. and strengthening its presence in Europe. JenaValve addresses a critical medical need by offering a less invasive alternative to traditional surgical valve replacement for patients with severe aortic regurgitation.

• Employees 180
• Founded 2013
• Annual Revenue $23500000
• Total Funding $295724556